Iron Deficiency Tied to Worse Response, Remodeling After CRT

Share this content:
Iron Deficiency Tied to Worse Response, Remodeling After CRT
Iron Deficiency Tied to Worse Response, Remodeling After CRT

THURSDAY, Dec. 22, 2016 (HealthDay News) -- For patients undergoing cardiac resynchronization therapy (CRT), iron deficiency is prevalent and is associated with clinical response and reverse cardiac remodeling, according to a study published in the Jan. 1 issue of The American Journal of Cardiology.

Pieter Martens, M.D., from Ziekenhuis Oost-Limburg in Genk, Belgium, and colleagues examined the impact of iron deficiency on clinical response and reverse cardiac remodeling and outcome after CRT in 541 patients with mean follow-up of 38 ± 22 months. The authors assessed New York Heart Association functional class, reverse cardiac remodeling on echocardiography, and clinical outcome retrospectively for patients with full iron status and complete blood count available at implantation.

The researchers found that the prevalence of iron deficiency was 56 percent at implantation. Less symptomatic improvement was seen at six months after implantation for patients with iron deficiency (P < 0.001). Patients with iron deficiency also had significantly lower decrease in left ventricular end-diastolic diameter and improvement in ejection fraction. Irrespective of the presence of anemia, there was a significant association for iron deficiency with an increased risk for heart failure admission or all-cause mortality (adjusted hazard ratio, 1.718).

"In conclusion, iron deficiency is prevalent and affects both clinical response and reverse cardiac remodeling after CRT implantation," the authors write. "Moreover, it is a powerful predictor of adverse clinical outcomes in CRT."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »